Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
CLEVELAND, Nov. 03, 2016 -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation is scheduled for Wednesday, November 16, 2016 at 3:45 pm ET in the Garrison conference room.
A live audio webcast will be available via the investor relations page of the Athersys website at www.athersys.com. A replay of the presentation will be archived on the Athersys website for those unable to listen live.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
